# TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment

> **NCT04391608** · PHASE4 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 80 (estimated)

## Conditions studied

- Renal Insufficiency
- Tenofovir

## Interventions

- **DRUG:** Switching to Tenofovir Alafenamide

## Key facts

- **NCT ID:** NCT04391608
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-09
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391608, "TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04391608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*